Search

Your search keyword '"O'Byrne, K."' showing total 1,157 results

Search Constraints

Start Over You searched for: Author "O'Byrne, K." Remove constraint Author: "O'Byrne, K."
1,157 results on '"O'Byrne, K."'

Search Results

3. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma

4. Whole transcriptome profiling of placental pathobiology in SARS-CoV-2 pregnancies identifies placental dysfunction signatures.

5. P1.23-04 Extracellular Small Vesicle Phosphorylated PD-L1 Liquid Biopsy Levels Correlate with Tumour Proportion Score (TPS) in NSCLC

8. P2.10-01 ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK+ NSCLC and ALK-inhibitor Resistance

11. P2.06-09 Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227

14. PPD04.02 First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227

15. Immunotherapeutic targets in non-small cell lung cancer.

16. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.

18. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

21. Immunotherapeutic targets in non-small cell lung cancer

23. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

27. First-line nivolumab + ipilimumab in advanced NSCLC : CheckMate 227 subpopulation analyses in Asian patients

28. Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures

30. Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update.

31. Understanding the tumor microenvironment in head and neck squamous cell carcinoma.

32. Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.

33. IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study.

36. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

37. 122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

38. 4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

40. FP07.05 DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

43. 1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)

46. IFI27 transcription is an early predictor for COVID-19 outcomes; a multi-cohort observational study

47. Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time?.

48. A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)

49. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

50. Radiographic and CT appearance of cavitary pulmonary lesions in a lamb

Catalog

Books, media, physical & digital resources